Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Halverson Website

David C. Halverson, M.D.

Selected Publications

1)  Castiello L, Mossoba M, Viterbo A, Sabatino M, Fellowes V, Foley JE, Winterton M, Halverson DC, Civini S, Jin P, Fowler DH, Stroncek DF.
Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells.
Cytotherapy. 15: 598-609, 2013.
[Journal]
2)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 122: 4129-39, 2013.
[Journal]
3)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. 121: 2864-74, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 2/25/2014.